Matthew Rosebraugh

754 total citations · 1 hit paper
21 papers, 513 citations indexed

About

Matthew Rosebraugh is a scholar working on Neurology, Psychiatry and Mental health and Biochemistry. According to data from OpenAlex, Matthew Rosebraugh has authored 21 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 5 papers in Psychiatry and Mental health and 3 papers in Biochemistry. Recurrent topics in Matthew Rosebraugh's work include Parkinson's Disease Mechanisms and Treatments (8 papers), Neurological disorders and treatments (4 papers) and Epilepsy research and treatment (4 papers). Matthew Rosebraugh is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (8 papers), Neurological disorders and treatments (4 papers) and Epilepsy research and treatment (4 papers). Matthew Rosebraugh collaborates with scholars based in United States and Germany. Matthew Rosebraugh's co-authors include Maurizio Facheris, Robert J. Padley, Jonathan S. George, Heidi S. Camp, J W Voss, Julie Parmentier, Annette Schwartz, Neil Wishart, Andrew J. Long and Michael Friedman and has published in prestigious journals such as Neurology, Annals of Neurology and Journal of the Neurological Sciences.

In The Last Decade

Matthew Rosebraugh

20 papers receiving 505 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

2018 276 citations Julie Parmentier, J W Voss et al. BMC Rheumatology profile →

Peers

Matthew Rosebraugh

NEURO

RHEUM

ONCOL

HEMAT

IMMUN

Linlin Wan China

A. Dimitrakopoulos Greece

Chun‐Sheng Yang China

Yasuaki Okuda Japan

Gabriele Di Comite Italy

P. Petiot France

Jie Lin China

Madhu P. Menon United States

Niamh Bermingham Ireland

Javier Olascoaga Spain

Linlin Wan China

Matthew Rosebraugh

81 ×0.5

NEURO

230 ×1.8

RHEUM

61 ×0.8

ONCOL

35 ×0.4

HEMAT

359 ×5.2

IMMUN

Citations per year, relative to Matthew Rosebraugh Matthew Rosebraugh (= 1×) peers Linlin Wan

Countries citing papers authored by Matthew Rosebraugh

Since Specialization

Citations

This map shows the geographic impact of Matthew Rosebraugh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew Rosebraugh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew Rosebraugh more than expected).

Fields of papers citing papers by Matthew Rosebraugh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthew Rosebraugh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew Rosebraugh. The network helps show where Matthew Rosebraugh may publish in the future.

Co-authorship network of co-authors of Matthew Rosebraugh

This figure shows the co-authorship network connecting the top 25 collaborators of Matthew Rosebraugh. A scholar is included among the top collaborators of Matthew Rosebraugh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew Rosebraugh. Matthew Rosebraugh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Han, Yi Rang, Anna Jeong, Suneel Gupta, et al.. (2025). Bioequivalence of Foslevodopa/Foscarbidopa continuous subcutaneous infusion to arm, thigh, or flank versus abdomen in healthy and advanced Parkinson’s disease individuals. Clinical Parkinsonism & Related Disorders. 13. 100359–100359.

Han, Yi Rang, et al.. (2025). Food Effect Study of Fosigotifator, an eIF2B Activator being developed as a Potential Treatment for Amyotrophic Lateral Sclerosis, Vanishing White Matter Disease, and Major Depressive Disorder (P8-2.011). Neurology. 104(7_Supplement_1). 1 indexed citations

Savaryn, John P., Richard L. Smith, Matthew Rosebraugh, et al.. (2024). Metabolite profiling of foslevodopa/foscarbidopa in plasma of healthy human participants by LC‐HRMS indicates no major differences compared to administration of levodopa/carbidopa intestinal gel. Pharmacology Research & Perspectives. 12(2). e1190–e1190. 3 indexed citations

Cho, Yong‐Yeon, et al.. (2023). A Phase 1 First-in-human Study to Investigate the Safety, Tolerability and Food Effect of ABBV-CLS-7262 (P6-4.002). Neurology. 100(17_supplement_2). 2 indexed citations

Rosebraugh, Matthew, et al.. (2022). Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to levodopa-carbidopa intestinal gel delivered to the jejunum. Parkinsonism & Related Disorders. 97. 68–72. 22 indexed citations

Rosebraugh, Matthew, et al.. (2022). Comparability of Foslevodopa/Foscarbidopa Pharmacokinetics in Healthy Asian and White Participants. Clinical Pharmacology in Drug Development. 12(4). 407–415. 4 indexed citations

Rosebraugh, Matthew, et al.. (2021). Foslevodopa/Foscarbidopa Is Well Tolerated and Maintains Stable Levodopa and Carbidopa Exposure Following Subcutaneous Infusion. Journal of Parkinson s Disease. 11(4). 1695–1702. 36 indexed citations

Rosebraugh, Matthew, Sven Stodtmann, Wei Liu, & Maurizio Facheris. (2021). Foslevodopa/foscarbidopa Subcutaneous Infusion Maintains Equivalent Levodopa Exposure to Levodopa-Carbidopa Intestinal Gel Delivered to the Jejunum (4468). Neurology. 96(15_supplement). 1 indexed citations

Rosebraugh, Matthew, Sven Stodtmann, Wei Liu, & Maurizio Facheris. (2021). Foslevodopa/foscarbidopa subcutaneous infusion maintains equivalent levodopa exposure to Levodopa-Carbidopa Intestinal Gel delivered to the jejunum. Journal of the Neurological Sciences. 429. 119570–119570. 2 indexed citations

10.

Rosebraugh, Matthew, Eric A. Voight, Ehab M. Moussa, et al.. (2021). Foslevodopa/Foscarbidopa: A New Subcutaneous Treatment for Parkinson's Disease. Annals of Neurology. 90(1). 52–61. 46 indexed citations

11.

Rosebraugh, Matthew, Philip R. Kym, Wei Liu, & Maurizio Facheris. (2020). ABBV-951 Maintains Stable Levodopa Exposure following Subcutaneous Infusion in Parkinson’s Disease Patients (543). Neurology. 94(15_supplement). 1 indexed citations

12.

Rosebraugh, Matthew, Philip R. Kym, Wei Liu, Maurizio Facheris, & Janet Benesh. (2019). A Novel Levodopa/Carbidopa Prodrug (ABBV-951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson’s Disease (P3.8-037). Neurology. 92(15_supplement). 9 indexed citations

13.

Rosebraugh, Matthew, et al.. (2019). Levodopa‐carbidopa intestinal gel high concentration formulation is clinically bioequivalent to commercial formulation. Pharmacology Research & Perspectives. 7(2). e00473–e00473. 3 indexed citations

14.

Ziemann, Adam, Matthew Rosebraugh, Bruce O. Barger, & Bruce Cree. (2019). A Phase 1, Multiple-dose Study of Elezanumab (ABT-555) in Patients with Relapsing Forms of Multiple Sclerosis (S56.001). Neurology. 92(15_supplement). 4 indexed citations

15.

Parmentier, Julie, J W Voss, Candace Graff, et al.. (2018). In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494). BMC Rheumatology. 2(1). 23–23. 276 indexed citations breakdown →

16.

Othman, Mohamed I. A., Matthew Rosebraugh, Krai Chatamra, Charles Locke, & Sandeep Dutta. (2017). Levodopa-Carbidopa Intestinal Gel Pharmacokinetics: Lower Variability than Oral Levodopa-Carbidopa. Journal of Parkinson s Disease. 7(2). 275–278. 32 indexed citations

17.

Rosebraugh, Matthew, John A. Widness, Demet Nalbant, Gretchen A. Cress, & Peter Veng‐Pedersen. (2013). Pharmacodynamically optimized erythropoietin treatment combined with phlebotomy reduction predicted to eliminate blood transfusions in selected preterm infants. Pediatric Research. 75(2). 336–342. 8 indexed citations

18.

Rosebraugh, Matthew, John A. Widness, Demet Nalbant, & Peter Veng‐Pedersen. (2012). A mathematical modeling approach to quantify the role of phlebotomy losses and need for transfusions in neonatal anemia. Transfusion. 53(6). 1353–1360. 31 indexed citations

19.

Rosebraugh, Matthew, John A. Widness, & Peter Veng‐Pedersen. (2012). Multidose optimization simulation of erythropoietin treatment in preterm infants. Pediatric Research. 71(1-4). 332–337. 9 indexed citations

20.

Rosebraugh, Matthew, John A. Widness, & Peter Veng‐Pedersen. (2011). Receptor-Based Dosing Optimization of Erythropoietin in Juvenile Sheep after Phlebotomy. Drug Metabolism and Disposition. 39(7). 1214–1220. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact